The missing link? LGMN connects hypoxia and immunosuppression in glioblastoma

Jonathan Mitchell; Bruno Colon; Defne Bayik; Justin D Lathia

doi:10.1016/j.xcrm.2023.101293

The missing link? LGMN connects hypoxia and immunosuppression in glioblastoma

Cell Rep Med. 2023 Nov 21;4(11):101293. doi: 10.1016/j.xcrm.2023.101293.

Authors

Jonathan Mitchell¹, Bruno Colon¹, Defne Bayik², Justin D Lathia³

Affiliations

¹ Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, FL, USA.
² Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, FL, USA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
³ Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA; Case Comprehensive Cancer Center, Cleveland, OH, USA. Electronic address: [email protected].

Abstract

In this issue, Pang and colleagues¹ identify the protease legumain as a potential immunotherapy target in glioblastoma that drives tumor-associated macrophages in response to hypoxia.

Publication types

Comment

MeSH terms

Cysteine Endopeptidases / physiology
Glioblastoma*
Humans
Hypoxia
Immunosuppression Therapy / adverse effects

Substances

Cysteine Endopeptidases

Grants and funding

T32 GM145462/GM/NIGMS NIH HHS/United States